SCPC Responds to CMS Proposed Part D Rule
Prioritize Independent Metrics for Prescription Drug Plans (PDPs) to Determine Long-Term Care (LTC) Pharmacy Payments and Appropriate Implementation of Opioid Crisis Response
Washington, DC – Commenting today on a recently-released Centers for Medicare and Medicaid Services (CMS) Proposed Rule regarding regulatory changes to key Medicare Part D provisions, the Senior Care Pharmacy Coalition (SCPC) offered policy recommendations.
President and CEO of SCPC, Alan G. Rosenbloom, pointed to two key recommendations as organization priorities requiring proper CMS implementation:
First, quality metrics that prescription drug plans (PDPs) use to evaluate and compensate long-term care (LTC) pharmacies must be developed independently. These metrics should be relevant to better outcomes for the LTC patient population and only evaluate practices within the control of LTC pharmacies that are relevant to the LTC patient population and within the control of LTC pharmacies. Rosenbloom says SCPC “strongly supports full disclosure, including public disclosure of quality measures PDPs use to evaluate and adjust payments to LTC pharmacies.”
Second, CMS must implement recent legislation Congress enacted in response to the opioid crisis as intended with respect to Part D beneficiaries living in nursing homes and other LTC facilities and settings.
Additionally, he continued, “SCPC urges CMS to add criteria PDPs must use before adopting pharmacy quality measures, including appropriate processes for metric development, independent validation of metrics, reasonable relationship between metrics and improved patient outcomes, use of metrics concerning practices within control of the pharmacy; use of metrics unrelated to financial performance of PDPs, PBMs or any pharmacies with corporate affiliations with PDPs, PBMs or any shared corporate parents, consistent application of metrics across all PDPs and metrics demonstrably relevant to the LTC patient population.”
Regarding opioid management provisions included in the Comprehensive Addiction and Recovery Act of 2016 and the within the SUPPORT for Patients and Communities Act of 2018, Rosenbloom stated: “We applaud Congressional and agency efforts to reduce and control prescription drug abuse in the Medicare Part D program. We further commend the agency for striking the appropriate balance in the Proposed Rule between this objective and the very low risk of prescription drug abuse among Part D beneficiaries residing in LTC facilities and other congregate and residential care settings.” He noted, however, that SCPC “emphasizes the need to implement fully the statutory provisions designed to exempt Part D beneficiaries in LTC facilities from certain opioid management requirements.”
####
The Senior Care Pharmacy Coalition (SCPC) is the only national organization exclusively representing the interests of LTC pharmacies. Its members operate in all 50 states and serve 850,000 patients daily in skilled nursing and assisted living facilities across the country. Visit seniorcarepharmacies.org to learn more.
Recent Posts
-
Senior Care Pharmacy Coalition Shares Comments with CMS Regarding Medicare Part D Restructuring Guidance: “Smoothing Provisions”
SCPC filed comments with CMS in response to their guidance on the implementation of the Medicare Part D restructuring portion of the Inflation Reduction Act (IRA).
-
Drug pricing efforts threaten ‘very existence’ of LTC pharmacies: reps
President Biden in his State of the Union address last week vowed to end “Big Pharma’s” grip on prescription drug pricing and cut costs for seniors and taxpayers by another $200 million.
But the president’s plans to expand his administration’s first-ever Medicare drug price negotiations could spell big trouble for the pharmacists who support seniors living in long-term care settings, advocates warned in response. -
President Biden Announces Desire to Cap Drug Prices for All Americans
In the State of the Union Address on March 7th, President Joseph Biden announced a proposal to expand the number of drugs targeted for annual price negotiations by Medicare and lower prescription drug costs for American families.
Stay in the Know
Get the latest news and updates on issues impacting the long-term pharmacy community.